Literature DB >> 1503618

Low-dose cyclosporin therapy of ocular inflammation: preliminary report of a long-term follow-up study.

H M Towler1, S L Lightman, J V Forrester.   

Abstract

Cyclosporin A (CsA) is an effective therapy for severe intraocular inflammation but nephrotoxicity and hypertension are major side effects even in low dose in combination with oral corticosteroids and clinical studies on the long-term effects of low-dose CsA therapy outside the field of organ transplantation are lacking. This multicentre, open, longitudinal study has been established to evaluate the long-term efficacy and side effects of low-dose CsA therapy (initial dose less than or equal to 5 mg/kg/day, with a maximum dose of 7 mg/kg/day, and total treatment duration greater than 3 months) in severe ocular inflammation where conventional therapy had failed to control the disease or caused intolerable side effects. Visual response to treatment, clinical signs and symptoms of side effects, biochemical and haematological parameters have been recorded at 3-monthly intervals since January 1987 and will continue until December 1993. Data for 74 patients (age 35.5 +/- 16.6 years) and 293 follow up visits are presented in this preliminary report. [table: see text] Other side effects include (% of all visits): hypertrichosis (4.2), headache (2.8), cramps (1.8), arthropathy (1.8), paraesthesiae (1.8), abdominal pain (1.5), weakness (1.5), dyspepsia (1.4), nausea (1.4), others (4).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1503618     DOI: 10.1016/0896-8411(92)90041-n

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  9 in total

Review 1.  Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A.

Authors:  A D Dick; M Azim; J V Forrester
Journal:  Br J Ophthalmol       Date:  1997-12       Impact factor: 4.638

Review 2.  Short term immunosuppressive therapy and long-term immunoregulation: promises and problems.

Authors:  J Isaacs; A Dick
Journal:  Br J Ophthalmol       Date:  1996-12       Impact factor: 4.638

Review 3.  Glucocorticoid receptor signaling in the eye.

Authors:  Rania S Sulaiman; Mahita Kadmiel; John A Cidlowski
Journal:  Steroids       Date:  2017-11-10       Impact factor: 2.668

Review 4.  Experimental approaches to specific immunotherapies in autoimmune disease: future treatment of endogenous posterior uveitis?

Authors:  A D Dick
Journal:  Br J Ophthalmol       Date:  1995-01       Impact factor: 4.638

Review 5.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

6.  Intranasal administration of retinal antigens suppresses retinal antigen-induced experimental autoimmune uveoretinitis.

Authors:  A D Dick; Y F Cheng; J Liversidge; J V Forrester
Journal:  Immunology       Date:  1994-08       Impact factor: 7.397

7.  Oligoclonal activation of CD4+ T lymphocytes in posterior uveitis.

Authors:  E J Feron; V L Calder; S L Lightman
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

8.  Cyclosporine for ocular inflammatory diseases.

Authors:  R Oktay Kaçmaz; John H Kempen; Craig Newcomb; Ebenezer Daniel; Sapna Gangaputra; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; Douglas A Jabs; Grace A Levy-Clarke; C Stephen Foster
Journal:  Ophthalmology       Date:  2010-01-19       Impact factor: 12.079

Review 9.  Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye.

Authors:  Diane D-S Tang-Liu; Andrew Acheampong
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.